SCHEMBL13073712

SCHEMBL13073712

C/C=C\c1cccc(Oc2ccc(F)cc2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NFE2L2 Q16236 7/20 0.57
▸ ALOX5 P09917 4/20 0.54
▸ MAPT P10636 2/20 0.54
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ TP53 P04637 1/20 0.54
▸ CYP1A2 P05177 1/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ CYP2D6 P10635 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54
▸ HPGD P15428 1/20 0.54
▸ ALOX15 P16050 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ ALOX12 P18054 1/20 0.54
▸ NFKB1 P19838 1/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ CYP2C19 P33261 1/20 0.54
▸ HIF1A Q16665 1/20 0.54
▸ LMNA P02545 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15177159 0.86 TLR4 (0.58) ALOX5MAPTMEN1KMT2ATSHR
SCHEMBL9338868 0.81 NFE2L2 (0.49) NFE2L2ALOX5MAPTMEN1KMT2A
SCHEMBL9517952 0.80 ALOX5 (0.58) NFE2L2ALOX5MAPTMEN1KMT2A
SCHEMBL9517950 0.80 ALOX5 (0.58) NFE2L2ALOX5MAPTMEN1KMT2A
SCHEMBL9161972 0.79 NFE2L2 (0.47) NFE2L2ALOX5MAPTMEN1KMT2A
SCHEMBL11215624 0.79 MAPT (0.50) NFE2L2ALOX5MAPTMEN1KMT2A
SCHEMBL184380 0.79 MAOA (0.62) NFE2L2ALOX5MAPTMEN1KMT2A
SCHEMBL30584498 0.79 MAOA (0.62) NFE2L2ALOX5MAPTMEN1KMT2A
SCHEMBL28893713 0.78 ALDH1A1 (0.57) ALOX5MAPTMEN1KMT2AALDH1A1
SCHEMBL9781107 0.78 TRPA1 (0.59) NFE2L2ALOX5MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825149-B2 Substituted imidazoles PFIZER LIMITED (GB) 2010-11-02 — — US disclosed
US-20090312326-A1 SUBSTITUTED IMIDAZOLES PFIZER LIMITED (GB) 2009-12-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312326-A1 SUBSTITUTED IMIDAZOLES ABL1, TYR, CYP3A4 NFE2L2 3385/4885ALOX5 4159/4885MAPT 316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback